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Abstract 
 
Production of organic particles in the micrometer/nanometer range can find applications in a wide 
range of areas, however for a number of materials it is not a straightforward task. In the present 
work pulsed laser ablation in liquid environment (PLAL) of meloxicam was studied aiming the 
production of near micrometer sized particles of this pharmaceutical ingredient. Targets pressed 
from crystalline meloxicam powder were placed in distilled water and irradiated with a focused 
beam of a frequency doubled (532 nm) nanosecond Nd:YAG laser at 4.2 – 9.4 J/cm2 fluence. 
Morphological investigation showed that the produced suspension contained particles in the ∼100 
nm to 10 µm size range, with 1.0 - 2.0 µm on average, which is about 10 times smaller than the size 
of the initial material. FTIR spectroscopic investigations demonstrated that the chemical 
composition was preserved, while XRD and calorimetric measurements indicated partial 
amorphization of meloxicam during the process. The overall results suggest that the particles are 
mostly produced by the fragmentation of the pressed target by the recoil forces of the ablating laser 
pulse. Long period sedimentation tests of the suspension combined with UV-Vis spectroscopic 
analysis showed that by the method of PLAL a greater fraction of the poorly water soluble 
meloxicam could be dispersed and dissolved in water in a pharmaceutically preferred formation 
than by simple dissolution of it. 
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1. Introduction 
 
Pulsed laser ablation (PLA) of different materials is a well-known process being used in several 
applications, especially on the field of material processing. It is extensively used for the micro-
machining of various inorganic and organic samples. Main application areas include the 
construction of given patterns, surface structures, micro-objects (by direct etching), and the 
fabrication of thin layers (by collection of the ablated fragments onto a substrate surface (PLD)). 
Several studies have already proved that PLA is suitable for the generation of micrometer- 
and submicrometer-sized particles from a wide range of materials in vacuum or gas environment. It 
has been demonstrated that by pulsed laser irradiation of iron target in water, iron-oxide particles 
can be formed at the liquid–solid interface [1]. Pulsed laser ablation in liquid (PLAL) is proved to 
be a promising route to produce clean colloids without any residual species in the case of metallic 
targets [2]. In the early 2000s PLAL became a well-established technique for the controlled 
fabrication of various nanoparticles (NPs) [3-5] for industrial, medical, biological or scientific 
research applications [6-10]. Thanks to the consistent and complementary theories and models, the 
process of PLAL is thoroughly described, and the method is reliably applicable for industrial NP 
fabrication [11-16]. 
In the beginning, PLAL has mainly been used to produce inorganic nanoparticles, such as 
diamond [17], metals and metal alloys [18-27], oxides [28-31] and semiconductor nanoparticles 
[32]. However, subsequent studies have shown that PLAL is also suitable for the production of 
organic nanoparticles, even though organic materials are more sensitive to optical radiation [33-39]. 
The obtained colloidal solution showed long time stability, typically for weeks or more, without the 
need of any additional surfactants due to the persistent Brownian motion of the nanoparticles in the 
solvent [37]. The size of the nanoparticles can be controlled by the experimental conditions such as 
the irradiating laser fluence [40,41], laser pulse duration [42] and wavelength [36]. The easy and 
high collectability of the created nanoparticles is a useful characteristic of laser ablation in the 
liquid phase.  
Initially, only a few, less-sensitive organic materials were applied for nanoparticle generation 
by PLAL, however in the last decade several studies presented successful NP production from 
different organic matters, like vanadyl phthalocyanine, quinacridone, melamine cyanurate, 
polyethylene terephtalate, beclomethasone dipropionate [35,37,43-48]. It has been shown that both 
micron-sized (1 to 10 µm) and submicron-sized (400 to 900 nm) paclitaxel and megestrol acetate 
particles can be produced successfully by PLAL [45,46]. 
One of the most important application fields of organic NPs is pharmacology. Smaller drug 
particles have higher surface to volume ratio, and therefore they have improved dissolution rate and 
transport characteristics, which greatly assist their fast absorption and uptake by the human cells 
[49,50]. It has also been shown that the amorphization of pharmaceuticals can further improve their 
dissolution properties since in the amorphous form there is no need to take over the crystal lattice 
binding energies during the dissolution process. PLAL could be a non-conventional approach in 
drug formulation, as a simple, clean (no additional chemicals are needed) and rapid wet grinding 
method. The medical applicability of a drug nanosuspension produced by PLAL strongly depends 
on the attained size of the suspended particles. For example the best uptake of the poorly water-
soluble oral and parenteral drugs can be achieved in the form of nanoparticles. For the intranasal 
and pulmonary application decreased size is a determinant factor. As pulmonary drugs, particles in 
the size range of 0.5 µm - 5 µm are the best absorbed in the lungs. Particles bigger than 5 µm are 
eliminated by the mucociliary clearance and can’t penetrate deep into the lungs, while, particles 
smaller than 0.5 µm are easily exhaled and also poorly absorbed [51]. Therefore, it is of particular 
interest to evaluate the size range of pulmonary drug particles prepared by PLAL.  
In this paper pulsed laser ablation of a poorly water-soluble material, meloxicam, was 
investigated in water. Meloxicam is a nonsteroidal anti-inflammatory analgesic and antipyretic drug 
(NSAID), and it is frequently used to treat rheumatoid arthritis, osteoarthritis and other joint 
diseases [52]. However, meloxicam has low solubility at physiological pH which impedes its 
clinical application. We studied the direct effect of laser fragmentation on the size decreasing and 
structural character of meloxicam, which is a potential model drug for our further nanosuspension 
formulations. The motivation of our study is to introduce a novel preparation method in drug 
preformulation and also to produce intermediate products for per os, nasal and pulmonary drug 
administration. 
 
2. Materials 
 
Meloxicam (4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-benzothiazine-3-car-boxamide-1,1-
dioxide) was obtained from EGIS Ltd., (Budapest, Hungary). It is a yellow powder with 10-50 µm 
average particle size, 100% crystalline. 
 
3. Experimental methods 
 
3.1. Preparation of nanosuspension by pulsed laser ablation in liquid 
 
A frequency doubled Q-switched Nd:YAG laser beam (FWHM = 8 ns, λ = 532 nm, f = 3 Hz) was 
focused by a fused silica lens (f=10 cm) onto a target placed in a rotating water-containing vessel. 
The targets were pastille pressed from commercially available meloxicam powder by a hydraulic 
compactor at 175 MPa pressure. The applied laser fluences were varied between 4.2 – 9.4 J/cm2 and 
the number of pulses was 48600. The meloxicam pastilles were placed in 20 ml distilled water 
(approximately 1.5 cm deep below the water surface) and clamped to the bottom of the vessel. In 
order to be treated evenly, the target was rotated under the beam during laser irradiation. 
 
3.2. Size and morphology studies 
 
After ablation an aliquot was taken from the solution, by avoiding the bottom of the vessel, in order 
to exclude pieces originating from occasional cracking and breaking of the surface layer of the 
pastille in consequence of the ablation induced mechanical forces. This step was important because 
these pieces could falsify the results of the investigations. Small droplets taken from the middle of 
the produced suspension were placed on silicon plates and left to dry for scanning electron 
microscopy investigations (SEM, Hitachi S-4700). Prior to imaging the samples were gold coated 
with a sputter coater (Bio-Rad SC 502). SEM images of some typical areas were recorded at 
different magnifications and analyzed using the ImageJ software. 
 
3.3. Structural characterization 
 
FTIR 
For chemical characterization, the ablated particles were analyzed by Fourier transform infrared 
spectroscopy (FTIR). A portion of the suspension was taken from the middle of the vessel, right 
after the ablation. A few mg ablated particles were obtained from the suspension by the evaporation 
of water at 60°C. Then this dry powder was ground with 150 mg KBr in an achate mortar and the 
mixture was pressed to a self-supporting disk for the FTIR analysis. 
FT-IR spectra were recorded with an FT-IR spectrometer (Thermo Nicolet AVATAR 330, LabX 
Midland, ON, Canada) between 4000 and 400 cm-1, at a resolution of 4 cm-1.  
 
XRPD 
Crystallinity of the dried meloxicam sample was characterized using an X-ray powder diffraction 
(XRPD) BRUKER D8 Advance X-ray diffractometer (Bruker AXS GmbH, Karlsruhe, Germany). 
The powder samples were loaded in contact with a plane quartz glass sample slide with an etched 
square. Cu-Kα1 radiation (λ = 1.5406 Å) source and a slit-detector was applied . Settings were as 
follows: the samples were scanned at 40 kV and 40 mA and the angular range was 3° to 40° 2θ, at a 
step time of 0.1 s and a step size of 0.007°. The crystallinity index was calculated on the basis of the 
following formula: Acryst/(Acryst+Aamorph), where Acryst and Aamorph denotes the area under the 
crystalline and amorphous peaks in the diffractogram, respectively. 
 
 
MDSC 
Differential scanning calorimetry (DSC) measurements were carried out on a TA Q20 (TA 
Instruments, USA) to examine and compare the thermal response of the ablated meloxicam with the 
original drugs’. The meloxicam powder was weighed into a Tzero aluminum sample pan and sealed 
with an aluminum Tzero lid. During modulated DSC (MDSC) measurements the samples were 
heated from 25 °C to 300 °C at a heating rate of 5°C/min with a temperature modulation of ±1°C in 
60 seconds periods, in inert atmosphere. Results were analyzed by Universal Analysis V4.5 
software. 
 
3.4. Sedimentation test (dissolution of meloxicam) 
 
The sedimentation of the ablated meloxicam particles in the aqueous medium was studied by 
extinction spectroscopy. The meloxicam suspension was produced by 43200 ablating laser pulses at 
9.4 J/cm2 fluence and the suspension was immediately transferred to a Shimadzu UV-2101PC VUV-
Vis spectrophotometer. Extinction spectra were recorded repeatedly with time. 
 
4. Experiments and results 
 
4.1. Particle size distribution investigations  
We compared the size distribution of the PLAL produced and the original meloxicam particles. Fig. 
1. illustrates the evaluation process for the particles generated with PLAL and the reference powder. 
The ImageJ software calculated the area of each patch being assigned to the individual particles, 
and determined the diameter of a hypothetical sphere which would have the same projected area. 
This diameter value will be considered as the size of the corresponding particle. Since only a small 
mass fraction of particles were smaller than 200 nm, a lower limit of 100 nm for the measured 
particle size was set.  
 
Fig. 1. Steps for determination of the particle size distribution from SEM images using image 
processing software (for details see text). 
 
Fig. 2. shows, that while the particles of the original meloxicam are in the 2-35 µm size range, all of 
the particles obtained from the laser generated meloxicam suspension are smaller than 10 µm, and a 
significant fraction is in the sub-micrometer size range. We have to note, that the overlapping of 
particles observed especially for the original meloxicam powder can affect the calculated average 
size of the particles to some extent, but not decisively.  The average dimensions of the meloxicam 
particles produced by PLAL at 9.4, 5.4 and 4.2 J/cm2 fluences were calculated to be 1.33, 1.05 and 
1.9 µm, respectively, while the original meloxicam powder particles were 16.5 µm on average size.  
 
Fig. 2. The size distribution of particles produced by ablation of meloxicam pastilles in water at 
different laser fluences. The original meloxicam powder was also investigated as reference. 
 
 
4.2. Morphological investigations 
Small droplets of the suspensions produced by different laser fluences were placed on silicon plates 
and left to dry for scanning electron microscopy (SEM) investigations and for comparison with the 
original meloxicam powder (Fig. 3(a)-(c)). The particles of the raw meloxicam powder were ∼2-40 
µm in size and displayed a lamellar crystalline structure, with sharp edges (Fig.3(c)). The particles 
obtained from the ablation suspension were ∼100 nm - 10 µm in size and less crystalline-like, 
having more rounded edges and showing traces of melting (Fig. 3(a),(b)). The morphology of the 
particles created at different laser energy densities was similar.  
 
Fig. 3. SEM images of the particles obtained from the meloxicam nanosuspension produced by (a) 
4.2 J/cm2 and (b) 9.4 J/cm2 laser fluences and of the original meloxicam powder particles (c). 
 
 
4.3. Chemical composition and structural analysis  
Our size-distribution measurements proved that the applied PLAL method is suitable for the particle 
size reduction. However, the chemical composition and crystal structure of the obtained particles 
are also important parameters for their pharmaceutical availability. 
 
FTIR 
The FTIR spectra showed no visible differences between the ablation produced particles and the 
original meloxicam powder in the investigated fluence range. Examining the fingerprint region (400 
– 1700 cm-1) the characteristic peaks matched to the reference (Fig. 4.). This indicates that the 
PLAL produced particles with reduced average size are chemically identical with the initial 
meloxicam.  
 
Fig. 4. FTIR spectra of the particles generated by ablation in distilled water milieu at different 
laser fluences and the original meloxicam powder as reference. 
 
XRPD 
The XRPD pattern of meloxicam particles produced by PLAL (Fig. 5.),was relatively weak, 
probably due to the small amount of sample available for the analysis, however the characteristic 
peaks of the original meloxicam powder were present at diffraction angles 2Θ of 13.22, 15.06, 
26.46 and 26.67°, indicating their identical crystalline structure [54]. According to the crystallinity 
index calculation the ablated particles have 93,3% crystalline fraction. 
 
Fig.5.: XRPD pattern of meloxicam particles produced by PLAL compared to the reference 
meloxicam powder. 
 MDSC 
As shown in Fig. 6. the melting point of the particles produced by laser ablation shifted to lower 
temperature (236 °C) as compared to the original crystalline meloxicam (258 °C). Earlier studies 
showed that this could be attributed to the amorphization of meloxicam to some degree [54, 55], 
which in our case can be the consequence of the laser treatment/fragmentation. 
 
 
Fig. 6. MDSC data of the particles produced by PLAL as compared to untreated meloxicam powder. 
 
 
4.4 Sedimentation test 
For the medical application of the meloxicam suspension it is important to know the stability of the 
colloid solution produced by PLAL.  
Extinction spectra were recorded at different times after the ablation (Fig. 7(a)). The 
intensity of the main meloxicam peak (at 360 nm) was plotted as a function of time (Fig. 7(b)). 
Over a 100 hour period it was found that the intensity of this peak first decreases, reaches a 
minimum value and then, after ∼50 hours, it starts to increase again until it reaches its final value 
after ∼90 hours. We suppose that during the time period of inspection two simultaneous processes, 
sedimentation and dissolution, occur and influence the extinction oppositely: i) in the beginning the 
relatively fast sedimentation of meloxicam particles results in the decrease of the extinction (mainly 
via the elimination of scattering sources from the bulk) ii) later on the relatively slow (and weak) 
chemical dissolution of meloxicam causes the slow increase of the extinction.  
The analytical balance measurement showed that the ablation entailed a 3.5 mg loss in mass 
of the target pastille. This means that the produced suspension contains totally 3.5 mg meloxicam in 
20 ml water in the form of particles and dissolved molecules. A reference suspension was made by 
adding 3.5 mg meloxicam powder to 20 ml distilled water and shacked for 2 minutes in ultrasonic 
bath. The extinction of the reference suspension was very low, and only a slight increase in it could 
be observed with time (Fig. 7(b)). The low initial extinction is attributed to the very small fraction 
of the particles floating in the bulk: most of the meloxicam powder is settled at the bottom of the 
cuvette or afloat on the surface of the water. After about 60 hours the extinction started to increase 
and then reached a constant value, indicating first the dissolution of meloxicam and then the 
saturation of the solution. (The solubility of meloxicam in water is 7.15 mg/L at 25°C [53].) 
  
Fig. 7. The extinction spectra of meloxicam suspension produced by 9.4 J/cm2 ablating fluence at 
different times elapsed (a). Graph (b) shows the intensity of the main meloxicam peak (at 360 nm) 
as a function of time for the PLAL generated (■) and reference solution (▲). Note the different 
scaling above and below the axis brake in (b). 
 
 
5. Discussion 
 
The absorption of laser photons in the surface layer of meloxicam pastille can result in thermal 
dissociation of the molecules. Thermal model calculations were carried out to estimate the 
temperature of the uppermost surface layer of the pastille after one laser pulse. We applied the 
Lambert-Beer law in order to estimate the temperature change as the function of depth by 
neglecting the heat conduction:  
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where α is the absorption coefficient at 532 nm, ρ is the density, c is the specific heat of meloxicam 
and F is the applied laser fluence. Due to lack of data in the literature, the absorption coefficient of 
meloxicam was determined by ellipsometry, which resulted in α=4 µm-1. For the mean specific heat 
of meloxicam in the temperature range 25-250 °C (i.e., below the decomposition temperature) we 
obtained 1800 J/(kgK) on the basis of Modulated Heat Flow measurement by Modulated 
Differential Scanning Calorimetry (MDSC). The thermal decomposition temperature of meloxicam 
was measured to be 258.7 oC, in good agreement with the data in PubChem open chemistry 
database (254 oC) [53].  
Our thermal model calculation demonstrated that the temperature of the upper 227-429 nm 
layer of the pastille exceeds the decomposition temperature of meloxicam in the whole range of 
laser fluence (4.2-9.4 J/cm2) applied. It is plausible that the fast decomposition of meloxicam 
molecules in the uppermost volume element gives rise to an explosion-like gas emission and 
expansion (Fig. 8(a)-(c)). The generated recoil forces tear off and accelerate softened/molten 
droplets and solid particles from the bottom of the ablation hole into the solution pulse by pulse 
(Fig. 8(c)-(d)). Thereby, a meloxicam suspension is formed. The typical size of the ejected grains 
ranges from tens of nanometers to a few micrometers, while the even smaller particles tend to 
aggregate and form larger particles. 
 
Fig. 8. Phenomenological model of the particle generation process during laser ablation of 
meloxicam pastille. 
 SEM images of the ablated area demonstrate that a significant amount of micrometer- to 
sub-micrometer-size debris can be found at the bottom of the ablation hole (Fig. 9(a)). At larger 
magnifications re-solidified molten droplets and jets can also be seen in the ablated area (Fig. 9(b)). 
Figures (c) and (d) show the pressed (intact upper surface) and the fracture surface of the original 
meloxicam pastille, respectively.  
 
Fig. 9. SEM images (a) and (b) of the bottom of a laser ablated hole (F= 5.4 J/cm2), captured at 
different magnifications. Solid debris (a) and re-solidified molten droplets and jets (b) can be seen 
well. As reference, the pressed (c) and the fracture (d) surface of the original meloxicam pastille is 
shown. 
 
 
6. Conclusion 
 
PLAL has been applied successfully for the production of highly stable aqueous suspension of near-
micrometer size meloxicam particles.  
The average size of the particles produced by 532 nm laser ablation of meloxicam pastilles 
fell in the 1.0 - 2.0 µm range. This is approximately one tenth of the average size of the original 
meloxicam powder particles (16.5 µm) and thereby it is more appropriate for the cellular uptake of 
the drug.  
We established that the ablated particles were chemically identical with the original 
meloxicam powder for all applied laser fluences.  
According to our observations, a fast sedimentation of the big particles occurs in the 
suspension during the first two days and after about 50 hours only the slow chemical dissolution of 
meloxicam can be seen. The higher extinction of the ablated suspension as compared to the 
reference meloxicam suspension during the whole time period of observation indicates that a larger 
amount of small particles could be dispersed in water by PLAL than by the simple dissolution of the 
original powder of the drug. The sedimentation measurements proved the stability of the PLAL 
produced suspension over a 100 hour time period as well.  
Our thermo-mechanical model calculations predicted that each laser pulse triggers the 
explosive decomposition of the target molecules in the upper 227-429 nm layer. The fast expansion 
of this upper volume element results in significant mechanical forces in its close proximity which 
can tear out meloxicam particles from the target pastille. The particles being ablated into the solvent 
on this (“gentle”) way suffer no chemical decomposition but still are much smaller than the 
particles of the original meloxicam powder. 
The crystal structure of meloxicam didn’t change during the ablation process, and only a 
slight decrease in the crystalline fraction was observed. The amorphization of meloxicam could also 
increase the dissolution rate and improve the bioavailability of the poorly water soluble drug 
(especially if accessing the nanometer size range as well) [55]. 
On the basis of our results we can conclude that pulsed laser ablation of meloxicam pastille 
in water is appropriate for the preparation of pure meloxicam suspension. The obtained size range 
of the particles predicts that PLAL may become a superior technique for the production of 
intermediate products for per os, nasal and pulmonary drug administration.  
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